Haleon (HLN) Non Operating Interest Expenses (2021 - 2023)
Haleon (HLN) posted Non Operating Interest Expenses of -$371.1 million for Q4 2023, down 139.16% on a QoQ basis from -$155.2 million in Q2 2023, and down 300.5% year-over-year from $185.1 million in Q4 2022.
Haleon (HLN) Non Operating Interest Expenses (2021 - 2023) Analysis & Trends
Haleon's Non Operating Interest Expenses history runs 3 years deep, the most recent figure standing at -$371.1 million for Q4 2023.
- Quarterly Non Operating Interest Expenses fell 300.5% year-over-year to -$371.1 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$735.1 million (changed N/A YoY) and the FY2024 annual result came in at -$490.9 million, up 1.83% from the prior year.
- Non Operating Interest Expenses was -$371.1 million for Q4 2023 at Haleon, down from -$155.2 million in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at -$18.9 million in Q4 2021 and bottomed at -$371.1 million in Q4 2023.
- A 3-year average of -$141.9 million and a median of -$106.7 million in 2022 frame the typical range for Non Operating Interest Expenses.
- Annual changes were most pronounced in 2022 — Non Operating Interest Expenses tumbled 391.0% — and 2023, when it tumbled 300.5%.
- Haleon's Non Operating Interest Expenses stood at -$18.9 million in 2021, then tumbled by 391.0% to -$92.7 million in 2022, then slumped by 300.5% to -$371.1 million in 2023.
- Business Quant data shows HLN's Non Operating Interest Expenses at -$371.1 million in Q4 2023, -$155.2 million in Q2 2023, and -$116.2 million in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -371.10 Mn |
| Jun 30, 2023 | -155.17 Mn |
| May 3, 2023 | -116.16 Mn |
| Dec 31, 2022 | -92.66 Mn |
| Sep 20, 2022 | -97.27 Mn |
| Dec 31, 2021 | -18.87 Mn |